Intensity Therapeutics, Inc. reported a net loss of $3.3 million for the first quarter ended March 31, 2025, an improvement from a $4.6 million net loss in the same period of 2024. Research and development expenses decreased to $2.2 million from $2.8 million, primarily due to lower contract manufacturing costs and stock-based compensation. General and administrative expenses also declined to $1.2 million from $1.9 million, reflecting cost savings from new administrative systems.
As of March 31, 2025, cash and cash equivalents stood at $0.9 million, highlighting significant liquidity challenges. In response to funding constraints, the company paused new site activations and patient enrollments for its Phase 3 INVINCIBLE-3 sarcoma study in March 2025, prioritizing funds for the INVINCIBLE-4 study. The company will continue to treat the 23 patients already enrolled in INVINCIBLE-3.
Despite these challenges, the company secured approximately $1.9 million in net proceeds from a public offering in April 2025. The Phase 2 INVINCIBLE-4 study for triple-negative breast cancer is actively recruiting in Switzerland, and the European Medicines Agency recently authorized its initiation in France, in collaboration with Unicancer.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.